SK-N-FIHomo sapiens (Human)Cancer cell line
Also known as: SKNF1, SK-N-F1, SKNFI, SK_N_FI, SN-N-FI
Quick Overview
SK-N-FI is a human neuroblastoma cell line used in cancer research.
Detailed Summary
Basic Information
| Database ID | CVCL_1702 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Bone marrow[UBERON:UBERON_0002371] |
Donor Information
| Age | 11 |
|---|---|
| Age Category | Pediatric |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Neuroblastoma |
|---|---|
| Lineage | Peripheral Nervous System |
| Subtype | Neuroblastoma |
| OncoTree Code | NBL |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000341_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Met246Arg (c.737T>G) | Homozygous | - | from parent cell line SK-N-FI |
| MutationUnexplicit | NF1 | Partial deletion | Homozygous | - | from parent cell line SK-N-FI |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition via modulation of neuronal gene signatures.
Segura M.F., Dyer M.A., Bernstein E.
Cancer Cell 36:512-527.e9(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.
Sci. Data 4:170033-170033(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
Lau L.M.S.
J. Neurooncol. 119:17-26(2014).
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.
Nat. Genet. 45:12-17(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
Int. J. Cancer 131:1556-1568(2012).
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Messiaen L.M., Versteeg R., Bernards R.
Cell 142:218-229(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Identification of ALK as a major familial neuroblastoma predisposition gene.
Maris J.M.
Nature 455:930-935(2008).
Mutations in PIK3CA are infrequent in neuroblastoma.";
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
BMC Cancer 6:177.1-177.10(2006).
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Maris J.M.
Genes Chromosomes Cancer 43:390-403(2005).
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Gabbert H.E., Poremba C.
Cancer Res. 64:3395-3405(2004).
Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.
Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.
Genes Chromosomes Cancer 32:126-135(2001).
Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.
Speleman F., Versteeg R.
Oncogene 10:291-297(1995).
Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies.
Minowada J.
J. Natl. Cancer Inst. 73:51-57(1984).
Human neuroblastoma cells and 13-cis-retinoic acid.";
Helson L., Helson C.
J. Neurooncol. 3:39-41(1985).
Vitamin E and human neuroblastoma.";
Helson L., Verma M., Helson C.
(In book chapter) Modulation and mediation of cancer by vitamins; Meyskens F.L., Prasad K.N. (eds.); pp.258-265; Karger; Basel; Switzerland (1983).
Tumor cell lines of the peripheral nervous system.";
Israel M.A., Thiele C.J.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York; USA (1994).